Yuzheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuzheng Zhang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Jordan Gauthier
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
9 shared publications - Kevin C. Barry
Department of Pathology and ImmunoX, University of California, San Francisco, San Francisco, California
9 shared publications - Kokoro Abe
Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington
9 shared publications - Nayvin W Chew
Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
9 shared publications - Renske J.E. van Den Bijgaart
Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands
9 shared publications - Shayan C. Avanessian
Department of Genome Sciences, University of Washington
9 shared publications
Latest Publications
- Open Access
Minimal Efficacy of Single-Agent Anti-PD-(L)1 Re-Exposure in Anti-PD-(L)1-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients
Background/Objectives: Anti-PD-(L)1 immune checkpoint inhibitors (ICIs) provide durable responses in nearly 50% of patients with advanced Merkel cell carcinoma (MCC). However, for those progressing on first-line ICI therapy, optimal subsequent therapy remains unclear. Although presumed to have limited benefit, the efficacy of re-exposure with anti-PD-(L)1 alone has not been formally reported. We assessed real-world outcomes of patients within a Seattle-based MCC repository who received this salvage approach. Methods: Among 106 patients who received salvage therapy after first-line ICI progression, 16 underwent single-agent anti-PD-(L)1 monotherapy re-exposure during salvage. Patients progressing >3 months after their last immunotherapy dose were excluded. Outcomes included progression-free survival (PFS), disease-specific survival (DSS), and objective response rate (ORR). Results: The median time from end of first-line ICI therapy to anti-PD-(L)1 re-exposure was 51 days (IQR 22–92). Most patients switched between PD-1 and PD-L1 inhibitors (n = 9), while others were re-exposed with the same agent (n = 5) or a different PD-1 inhibitor (n = 2). One of 16 patients experienced a partial response with the same PD-1 inhibitor (ORR 6%; 95% CI: 0.2–30%) at 3 months after re-exposure, followed by progression 10 months after re-exposure. Median PFS was 2.2 months (95% CI: 1.3–5.1 months), and median DSS was 14.7 months (95% CI: 10.4–NR). Conclusions: These data suggest that re-exposure with anti-PD-(L)1 monotherapy confers minimal and short-lived benefit in ICI-refractory MCC, reinforcing the need to develop alternative salvage strategies. Future trials for ICI-refractory MCC mandating an ICI monotherapy arm are unlikely to be appealing to patients or physicians based on a low chance of clinical benefit for this approach.
Open AccessMinimal Efficacy of Single-Agent Anti-PD-(L)1 Re-Exposure in Anti-PD-(L)1-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients
Background/Objectives: Anti-PD-(L)1 immune checkpoint inhibitors (ICIs) provide durable responses in nearly 50% of patients with advanced Merkel cell carcinoma (MCC). However, for those progressing on first-line ICI therapy, optimal subsequent therapy remains unclear. Although presumed to have limited benefit, the efficacy of re-exposure with anti-PD-(L)1 alone has not been formally reported. We assessed real-world outcomes of patients within a Seattle-based MCC repository who received this salvage approach. Methods: Among 106 patients who received salvage therapy after first-line ICI progression, 16 underwent single-agent anti-PD-(L)1 monotherapy re-exposure during salvage. Patients progressing >3 months after their last immunotherapy dose were excluded. Outcomes included progression-free survival (PFS), disease-specific survival (DSS), and objective response rate (ORR). Results: The median time from end of first-line ICI therapy to anti-PD-(L)1 re-exposure was 51 days (IQR 22–92). Most patients switched between PD-1 and PD-L1 inhibitors (n = 9), while others were re-exposed with the same agent (n = 5) or a different PD-1 inhibitor (n = 2). One of 16 patients experienced a partial response with the same PD-1 inhibitor (ORR 6%; 95% CI: 0.2–30%) at 3 months after re-exposure, followed by progression 10 months after re-exposure. Median PFS was 2.2 months (95% CI: 1.3–5.1 months), and median DSS was 14.7 months (95% CI: 10.4–NR). Conclusions: These data suggest that re-exposure with anti-PD-(L)1 monotherapy confers minimal and short-lived benefit in ICI-refractory MCC, reinforcing the need to develop alternative salvage strategies. Future trials for ICI-refractory MCC mandating an ICI monotherapy arm are unlikely to be appealing to patients or physicians based on a low chance of clinical benefit for this approach.
- Open Access
- 30 June 2026
- Published by MDPI AG in Preprints.org
Minimal Efficacy of Single-Agent Anti-PD(L)1 Rechallenge in Immunotherapy-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients
Background/Objectives: Anti-PD(L)1 immune checkpoint inhibitors (ICI) provide durable responses in nearly 50% of patients with advanced Merkel cell carcinoma (MCC). However, for those progressing on first-line ICI, optimal subsequent therapy remains unclear. Although presumed to have limited benefit, the efficacy of rechallenge with anti-PD(L)1 alone has not been formally reported. We assessed real-world outcomes of patients within a Seattle-based MCC repository who received this salvage approach. Methods: Among 106 patients who received salvage therapy after first-line ICI progression, 16 underwent single-agent ICI monotherapy rechallenge during salvage. Patients progressing >3 months after their last immunotherapy dose were excluded. Outcomes included progression-free survival (PFS), disease-specific survival (DSS), and objective response rate (ORR). Results: The median time from end of first-line ICI to anti-PD(L)1 rechallenge was 51 days (IQR 22-92). Most patients switched between PD-1 and PD-L1 inhibitors (n=11), while others were rechallenged with the same agent (n=3) or a different PD-1 inhibitor (n=2). One of 16 patients experienced a partial response with the same PD-1 inhibitor (ORR 6%; 95% CI: 0.2-30%) at 3 months after rechallenge followed by progression 10 months after rechallenge. Median PFS was 2.2 months (95% CI: 1.3-5.1 months), and median DSS was 14.7 months (95% CI: 10.4-NR). Conclusions: These data suggest that rechallenge with anti-PD(L)1 monotherapy confers minimal and short-lived benefit in ICI-refractory MCC, reinforcing the need to develop alternative salvage strategies. Future trials for ICI-refractory MCC mandating an ICI-monotherapy arm are unlikely to be appealing to patients or physicians based on a low chance of clinical benefit for this approach.
- 30 June 2026
- Published by MDPI AG in Preprints.org
Open AccessMinimal Efficacy of Single-Agent Anti-PD(L)1 Rechallenge in Immunotherapy-Refractory Merkel Cell Carcinoma: A Retrospective Cohort Study of 16 Patients
Background/Objectives: Anti-PD(L)1 immune checkpoint inhibitors (ICI) provide durable responses in nearly 50% of patients with advanced Merkel cell carcinoma (MCC). However, for those progressing on first-line ICI, optimal subsequent therapy remains unclear. Although presumed to have limited benefit, the efficacy of rechallenge with anti-PD(L)1 alone has not been formally reported. We assessed real-world outcomes of patients within a Seattle-based MCC repository who received this salvage approach. Methods: Among 106 patients who received salvage therapy after first-line ICI progression, 16 underwent single-agent ICI monotherapy rechallenge during salvage. Patients progressing >3 months after their last immunotherapy dose were excluded. Outcomes included progression-free survival (PFS), disease-specific survival (DSS), and objective response rate (ORR). Results: The median time from end of first-line ICI to anti-PD(L)1 rechallenge was 51 days (IQR 22-92). Most patients switched between PD-1 and PD-L1 inhibitors (n=11), while others were rechallenged with the same agent (n=3) or a different PD-1 inhibitor (n=2). One of 16 patients experienced a partial response with the same PD-1 inhibitor (ORR 6%; 95% CI: 0.2-30%) at 3 months after rechallenge followed by progression 10 months after rechallenge. Median PFS was 2.2 months (95% CI: 1.3-5.1 months), and median DSS was 14.7 months (95% CI: 10.4-NR). Conclusions: These data suggest that rechallenge with anti-PD(L)1 monotherapy confers minimal and short-lived benefit in ICI-refractory MCC, reinforcing the need to develop alternative salvage strategies. Future trials for ICI-refractory MCC mandating an ICI-monotherapy arm are unlikely to be appealing to patients or physicians based on a low chance of clinical benefit for this approach.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Gating strategy to define NK cell subsets and activation in murine tumors.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Gating strategy to define NK cell subsets and activation in murine tumors.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Interleukin-2 and interleukin-15 promote Flt3L-dependent NK cell control of cDC1 abundance.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Interleukin-2 and interleukin-15 promote Flt3L-dependent NK cell control of cDC1 abundance.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Cytokine and activating receptor stimulation leads to NK cell activation.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Cytokine and activating receptor stimulation leads to NK cell activation.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells are the predominant lymphocyte producer of Flt3l in the TME, particularly upon activation.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells are the predominant lymphocyte producer of Flt3l in the TME, particularly upon activation.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Supplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Supplementary Table S1 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Data from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells play a critical role in anticancer immunity through their direct cytotoxicity and production of cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L). NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune responses. In this study, we show that NK cell production of Flt3l in the tumor is regulated by activation and that activation by IL2 and IL15 uniquely induced Flt3L expression in NK cells. In melanoma, IL2 signaling in NK cells led to increased Flt3L production, which boosted cDC1 abundance in the tumor and improved anti–PD-1 immunotherapy response. Furthermore, NK cell subsets differentially regulated Flt3l in the tumor, with CD11b−CD27+ NK cells in mouse tumors enriched for IL2 family signaling and upregulating Flt3l upon activation. Consistently, human CD56brightCD16− NK cells more strongly correlated with cDC1 and FLT3LG expression than other NK cell subsets across multiple human melanoma datasets and cancer indications. This mechanistic study of NK cell regulation of FLT3LG and control of the NK cell–cDC1 axis provides insights and strategies for the development of more effective cancer immunotherapies.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
NK cells play a critical role in anticancer immunity through their direct cytotoxicity and production of cytokines, such as FMS-like tyrosine kinase 3 ligand (Flt3L). NK cell production of Flt3L controls conventional type I dendritic cell (cDC1) abundance in the tumor and promotes protective immune responses. In this study, we show that NK cell production of Flt3l in the tumor is regulated by activation and that activation by IL2 and IL15 uniquely induced Flt3L expression in NK cells. In melanoma, IL2 signaling in NK cells led to increased Flt3L production, which boosted cDC1 abundance in the tumor and improved anti–PD-1 immunotherapy response. Furthermore, NK cell subsets differentially regulated Flt3l in the tumor, with CD11b−CD27+ NK cells in mouse tumors enriched for IL2 family signaling and upregulating Flt3l upon activation. Consistently, human CD56brightCD16− NK cells more strongly correlated with cDC1 and FLT3LG expression than other NK cell subsets across multiple human melanoma datasets and cancer indications. This mechanistic study of NK cell regulation of FLT3LG and control of the NK cell–cDC1 axis provides insights and strategies for the development of more effective cancer immunotherapies.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Identifying human NK cell subsets and the correlation between components of the NK cell-cDC1 axis in human metastatic melanoma.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
Identifying human NK cell subsets and the correlation between components of the NK cell-cDC1 axis in human metastatic melanoma.
- Open Access
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
IL-2-treated NK cells augment ICB responses while IL-18-treated NK cells do not.
- 8 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti–PD-1 Immunotherapy
IL-2-treated NK cells augment ICB responses while IL-18-treated NK cells do not.